Loading...
Loading...
CHICAGO, Dec. 11, 2019 /PRNewswire/ -- Ronald L Chez, a private investor, files a 13D for Alimera Sciences, Inc. ALIM. Alimera returns to growth in the 3rd quarter and expects continued progress in the 4th quarter. The Company is in a strong position to succeed with their unique approach to DME.
Media contact: Elias Matsakis, Holland & Knight LLP
SOURCE Ronald L. Chez, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in